EA201791816A1 - Ингибиторы kv1.3 и их применение в медицине - Google Patents

Ингибиторы kv1.3 и их применение в медицине

Info

Publication number
EA201791816A1
EA201791816A1 EA201791816A EA201791816A EA201791816A1 EA 201791816 A1 EA201791816 A1 EA 201791816A1 EA 201791816 A EA201791816 A EA 201791816A EA 201791816 A EA201791816 A EA 201791816A EA 201791816 A1 EA201791816 A1 EA 201791816A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
alkyl
hydrogen
nrr
heterocycloalkyl
Prior art date
Application number
EA201791816A
Other languages
English (en)
Other versions
EA037194B1 (ru
Inventor
Штефан Таслер
Ильга Криммельбайн
Юрген Краус
Мирко Зая
Original Assignee
4Ск Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Ск Аг filed Critical 4Ск Аг
Publication of EA201791816A1 publication Critical patent/EA201791816A1/ru
Publication of EA037194B1 publication Critical patent/EA037194B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Abstract

Изобретение относится к соединению общей формулы (II) или его соли или сольвату, а также к применению в медицине, которое их предусматривает,где Авыбран из группы, состоящей из N и C-R; Aвыбран из группы, состоящей из N и C-R; Aвыбран из группы, состоящей из N и C-R; A, и A, и Aнезависимо выбраны из группы, состоящей из N и C-R; Rвыбран из группы, состоящей из водорода, (C-C)алкила, галогена, (C-C)алкокси и (C-C)галогеналкила; Rвыбран из группы, состоящей из водорода, галогена и (C-C)алкила; Rвыбран из группы, состоящей из водорода, (C-C)алкила, NRR, (C-C)алкил-NRRи циано, где Rи Rнезависимо выбраны из группы, состоящей из водорода, (C-C)циклоалкила, (C-C)гетероциклоалкила и (C-C)алкила, или Rи Rвместе с атомом азота, к которому они присоединены, образуют 5-7-членное гетероциклическое кольцо, необязательно содержащее в дополнение к вышеуказанному атому азота дополнительную гетероатомную группу, выбранную из группы, состоящей из O и NR, где Rвыбран из группы, состоящей из водорода, метила, ацетила и формила; Y выбран из группы, состоящей из O и S; Rвыбран из группы, состоящей из (C-C)алкила, (C-C)циклоалкила и (C-C)гетероциклоалкила; и Rвыбран из группы, состоящей из водорода, (C-C)алкила и (C-C)алкокси; при этом определенные конкретные соединения исключены согласно условию, и к способам получения данных соединений.
EA201791816A 2015-03-13 2016-03-14 Ингибиторы kv1.3 и их применение в медицине EA037194B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159080 2015-03-13
PCT/EP2016/055451 WO2016146583A1 (en) 2015-03-13 2016-03-14 Kv1.3 inhibitors and their medical application

Publications (2)

Publication Number Publication Date
EA201791816A1 true EA201791816A1 (ru) 2018-04-30
EA037194B1 EA037194B1 (ru) 2021-02-18

Family

ID=52736854

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791816A EA037194B1 (ru) 2015-03-13 2016-03-14 Ингибиторы kv1.3 и их применение в медицине

Country Status (27)

Country Link
US (4) US10822345B2 (ru)
EP (1) EP3268374B1 (ru)
JP (1) JP6506409B2 (ru)
KR (1) KR20170137056A (ru)
CN (1) CN107548397B (ru)
AU (1) AU2016232338B2 (ru)
BR (1) BR112017019439A2 (ru)
CA (1) CA2979503A1 (ru)
CY (1) CY1122470T1 (ru)
DK (1) DK3268374T3 (ru)
EA (1) EA037194B1 (ru)
ES (1) ES2762938T3 (ru)
HK (1) HK1243997B (ru)
HR (1) HRP20192258T1 (ru)
IL (1) IL254391B (ru)
LT (1) LT3268374T (ru)
MX (1) MX2017011650A (ru)
PH (1) PH12017501652B1 (ru)
PL (1) PL3268374T3 (ru)
PT (1) PT3268374T (ru)
RS (1) RS59758B1 (ru)
SG (1) SG11201707284PA (ru)
SI (1) SI3268374T1 (ru)
TW (1) TWI701249B (ru)
UA (1) UA121493C2 (ru)
WO (1) WO2016146583A1 (ru)
ZA (1) ZA201705561B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3684762B1 (en) 2017-09-20 2023-05-03 Lead Discovery Center GmbH Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
US10703735B2 (en) 2018-07-25 2020-07-07 Lead Discovery Center Gmbh 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
AU2019334065A1 (en) * 2018-09-07 2021-04-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compounds acting on CRBN proteins
JP7525507B2 (ja) 2019-03-20 2024-07-30 リード ディスカバリー センター ゲーエムベーハー キノリン誘導体、それらの調製のための方法及びがんの治療のためのその使用
CA3183732A1 (en) 2020-05-20 2021-11-25 AMO Ireland Azacoumarin and azathiocoumarin derivatives for use in optically active devices
CN115960112B (zh) * 2023-02-03 2024-02-20 北京大学深圳医院（北京大学深圳临床医学院） 一种花椒毒醇衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5729765A (en) 1980-10-08 1982-02-17 Yuuichi Yanagi Melting of snow on roof
US6861405B2 (en) 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
AUPS127202A0 (en) 2002-03-20 2002-04-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic ion channel blocking agents and methods of use thereof
US7772408B1 (en) 2002-08-29 2010-08-10 The Regents Of The University Of California Substituted 5-alkoxypsoralens as inhibitors of potassium channel activity in lymphocytes and other cells
AU2003288925A1 (en) 2002-10-08 2004-05-04 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
ITPD20020325A1 (it) 2002-12-18 2004-06-19 Consorzio Interuniversitario Nazionale La Chimic Sintesi di aniline funzionalizzate mono-n-sostituite.
CN100486245C (zh) 2003-07-31 2009-05-06 中兴通讯股份有限公司 一种支持多媒体消息版权保护的多媒体消息业务实现方法
US7557138B2 (en) * 2004-10-04 2009-07-07 The Regents Of The University Of California 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel
AU2006225071B2 (en) 2005-03-15 2012-01-12 The Regents Of The University Of California Novel potassium channel blockers and uses thereof
CA2619480A1 (en) 2005-08-17 2007-02-22 Solvay Pharmaceuticals Gmbh Method of using potassium channel inhibiting compounds
US20100239562A1 (en) 2006-05-22 2010-09-23 The Johns Hopkins University Kv CHANNELS IN NEURODEGENERATION AND NEUROPROTECTION
NZ575686A (en) 2006-10-04 2012-02-24 Bionomics Ltd Novel chromenone potassium channel blockers and uses thereof
WO2008040057A1 (en) 2006-10-04 2008-04-10 Bionomics Limited Novel benzofuran potassium channel blockers and uses thereof
CN101307056B (zh) * 2007-05-16 2011-04-27 中国科学院上海药物研究所 线型呋喃香豆素衍生物、其制备方法和用途、以及包含该衍生物的药物组合物
KR20100087148A (ko) 2007-10-04 2010-08-03 바이오노믹스 리미티드 신규한 아릴 칼륨 채널 차단제 및 그의 용도
US9114102B2 (en) 2007-11-07 2015-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting ABCG2 and related treatments
US8507539B2 (en) 2008-06-13 2013-08-13 Bionomics Limited Potassium channel blockers and uses thereof
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
ES2345527B1 (es) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima.
AR074558A1 (es) 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
CA2774327C (en) 2009-09-15 2019-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same
CN102091067B (zh) * 2009-12-09 2013-04-10 中国科学院上海药物研究所 呋喃香豆素类化合物在制备药物中的新用途
WO2011073277A1 (en) 2009-12-16 2011-06-23 Evotec Ag PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS
WO2011073269A1 (en) 2009-12-16 2011-06-23 Evotec Ag Piperidine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
JP6166858B2 (ja) 2011-03-02 2017-07-19 バイオインセプト、エルエルシー 細胞内損傷の治療のための組成物および方法
US20140171455A1 (en) * 2011-06-09 2014-06-19 The Regents Of The University Of California Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition
IN2014CN03333A (ru) 2011-10-03 2015-07-03 Univ California
CA3019297A1 (en) * 2016-03-31 2017-10-05 Toray Industries, Inc. Method for producing protein

Also Published As

Publication number Publication date
WO2016146583A1 (en) 2016-09-22
CN107548397B (zh) 2020-12-29
CN107548397A (zh) 2018-01-05
EA037194B1 (ru) 2021-02-18
UA121493C2 (uk) 2020-06-10
KR20170137056A (ko) 2017-12-12
PH12017501652A1 (en) 2018-03-12
TW201639843A (zh) 2016-11-16
EP3268374B1 (en) 2019-09-25
JP6506409B2 (ja) 2019-04-24
HK1243997B (zh) 2020-06-26
SG11201707284PA (en) 2017-10-30
CA2979503A1 (en) 2016-09-22
DK3268374T3 (da) 2020-01-02
US10723743B2 (en) 2020-07-28
US10822345B2 (en) 2020-11-03
ES2762938T3 (es) 2020-05-26
US20190185483A1 (en) 2019-06-20
IL254391A0 (en) 2017-11-30
HRP20192258T1 (hr) 2020-03-20
AU2016232338A1 (en) 2017-10-05
IL254391B (en) 2021-02-28
RS59758B1 (sr) 2020-02-28
PL3268374T3 (pl) 2020-05-18
BR112017019439A2 (pt) 2018-05-15
PH12017501652B1 (en) 2018-03-12
ZA201705561B (en) 2020-01-29
AU2016232338B2 (en) 2020-09-03
PT3268374T (pt) 2019-12-23
CY1122470T1 (el) 2021-01-27
MX2017011650A (es) 2018-02-09
US20200339592A1 (en) 2020-10-29
EP3268374A1 (en) 2018-01-17
LT3268374T (lt) 2020-03-10
US20180051034A1 (en) 2018-02-22
TWI701249B (zh) 2020-08-11
SI3268374T1 (sl) 2020-03-31
US20200377514A1 (en) 2020-12-03
JP2018507892A (ja) 2018-03-22

Similar Documents

Publication Publication Date Title
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
RU2016135922A (ru) Терапевтические соединения и композиции
EA201691302A1 (ru) Новые гетероциклические соединения
EA201690760A1 (ru) Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
EA201592198A1 (ru) Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201591586A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201290260A1 (ru) Бензимидазол-имидазольные производные
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
AR099495A1 (es) Derivados de amida, antagonistas de orexina

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM